FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969499569> ?p ?o ?g. }

• W1969499569 endingPage "864.e9" @default.
• W1969499569 startingPage "853" @default.
• W1969499569 abstract "Background & AimsLittle is known about functions of microRNA (miR) passenger strands (miR*) or their roles in tumor development or progression. We screened for miRs and miR* with levels that were altered in metastatic colorectal cancer (CRC) cells and human tumor samples and investigated their targets and effects on cell function and tumor progression in mice.MethodsWe performed array-based profile analysis to identify miRs with levels that were increased more than 2-fold in metastatic (SW620) CRC cells compared with nonmetastatic (SW480) cells. Quantitative polymerase chain reaction and in situ hybridization analyses were used to measure miRNA levels in CRC cell lines and human tumor samples. We used miRNA duplex mimics or inhibitors to increase and decrease levels of miRNA in CRC cells and assessed their activities and ability to form metastatic xenograft tumors in nude mice.ResultsLevels of miR-221* and miR-224 were reduced in metastatic compared with nonmetastatic CRC cells; levels in human tumor samples correlated inversely with tumor stage and metastasis to lymph nodes as well as patient survival times. SW480 cells transfected with miR-221* or miR-224 inhibitors had increased motility in vitro compared with SW480 control cells and formed larger, more metastatic tumors when injected into mice. SW620 cells transfected with miR-221* or miR-224 mimics had reduced migration and motility in vitro and formed smaller tumors with fewer metastases in mice compared with control SW620 cells. We identified the 3′ untranslated region of MBD2 messenger RNA as a target of miR-221* and miR-224. MBD2 silences the gene encoding maspin, a suppressor of metastasis. In CRC cells, we found that miR-221* and miR-224 increase the expression of maspin through MBD2 down-regulation.ConclusionsIn metastatic CRC cells, reduced levels of miR-221* and miR-224 increase levels of MBD2, thereby decreasing expression of the metastasis suppressor maspin. Increased activities of miR-221* and miR-224 reduce growth and metastasis of CRC xenograft tumors in mice; these miRs might be developed as therapeutic reagents or biomarkers of CRC progression. Little is known about functions of microRNA (miR) passenger strands (miR*) or their roles in tumor development or progression. We screened for miRs and miR* with levels that were altered in metastatic colorectal cancer (CRC) cells and human tumor samples and investigated their targets and effects on cell function and tumor progression in mice. We performed array-based profile analysis to identify miRs with levels that were increased more than 2-fold in metastatic (SW620) CRC cells compared with nonmetastatic (SW480) cells. Quantitative polymerase chain reaction and in situ hybridization analyses were used to measure miRNA levels in CRC cell lines and human tumor samples. We used miRNA duplex mimics or inhibitors to increase and decrease levels of miRNA in CRC cells and assessed their activities and ability to form metastatic xenograft tumors in nude mice. Levels of miR-221* and miR-224 were reduced in metastatic compared with nonmetastatic CRC cells; levels in human tumor samples correlated inversely with tumor stage and metastasis to lymph nodes as well as patient survival times. SW480 cells transfected with miR-221* or miR-224 inhibitors had increased motility in vitro compared with SW480 control cells and formed larger, more metastatic tumors when injected into mice. SW620 cells transfected with miR-221* or miR-224 mimics had reduced migration and motility in vitro and formed smaller tumors with fewer metastases in mice compared with control SW620 cells. We identified the 3′ untranslated region of MBD2 messenger RNA as a target of miR-221* and miR-224. MBD2 silences the gene encoding maspin, a suppressor of metastasis. In CRC cells, we found that miR-221* and miR-224 increase the expression of maspin through MBD2 down-regulation. In metastatic CRC cells, reduced levels of miR-221* and miR-224 increase levels of MBD2, thereby decreasing expression of the metastasis suppressor maspin. Increased activities of miR-221* and miR-224 reduce growth and metastasis of CRC xenograft tumors in mice; these miRs might be developed as therapeutic reagents or biomarkers of CRC progression." @default.
• W1969499569 created "2016-06-24" @default.
• W1969499569 creator A5010046302 @default.
• W1969499569 creator A5028151790 @default.
• W1969499569 creator A5053945938 @default.
• W1969499569 creator A5056106013 @default.
• W1969499569 creator A5081422845 @default.
• W1969499569 creator A5084693085 @default.
• W1969499569 creator A5086086952 @default.
• W1969499569 date "2013-10-01" @default.
• W1969499569 modified "2023-10-16" @default.
• W1969499569 title "Decreased Levels of miR-224 and the Passenger Strand of miR-221 Increase MBD2, Suppressing Maspin and Promoting Colorectal Tumor Growth and Metastasis in Mice" @default.
• W1969499569 cites W1502713173 @default.
• W1969499569 cites W1520425169 @default.
• W1969499569 cites W1637312052 @default.
• W1969499569 cites W1973165047 @default.
• W1969499569 cites W1978337436 @default.
• W1969499569 cites W1981570640 @default.
• W1969499569 cites W1982343022 @default.
• W1969499569 cites W1983428971 @default.
• W1969499569 cites W1987851658 @default.
• W1969499569 cites W2005889517 @default.
• W1969499569 cites W2023945347 @default.
• W1969499569 cites W2031621381 @default.
• W1969499569 cites W2031830818 @default.
• W1969499569 cites W2037429771 @default.
• W1969499569 cites W2044643325 @default.
• W1969499569 cites W2047529648 @default.
• W1969499569 cites W2055818953 @default.
• W1969499569 cites W2061488553 @default.
• W1969499569 cites W2081601075 @default.
• W1969499569 cites W2084060563 @default.
• W1969499569 cites W2085667285 @default.
• W1969499569 cites W2091651379 @default.
• W1969499569 cites W2095852413 @default.
• W1969499569 cites W2106787323 @default.
• W1969499569 cites W2133176657 @default.
• W1969499569 cites W2135191999 @default.
• W1969499569 cites W2149685907 @default.
• W1969499569 cites W2153775316 @default.
• W1969499569 cites W2157754963 @default.
• W1969499569 doi "https://doi.org/10.1053/j.gastro.2013.06.008" @default.
• W1969499569 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3783518" @default.
• W1969499569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23770133" @default.
• W1969499569 hasPublicationYear "2013" @default.
• W1969499569 type Work @default.
• W1969499569 sameAs 1969499569 @default.
• W1969499569 citedByCount "81" @default.
• W1969499569 countsByYear W19694995692013 @default.
• W1969499569 countsByYear W19694995692014 @default.
• W1969499569 countsByYear W19694995692015 @default.
• W1969499569 countsByYear W19694995692016 @default.
• W1969499569 countsByYear W19694995692017 @default.
• W1969499569 countsByYear W19694995692018 @default.
• W1969499569 countsByYear W19694995692019 @default.
• W1969499569 countsByYear W19694995692020 @default.
• W1969499569 countsByYear W19694995692021 @default.
• W1969499569 countsByYear W19694995692022 @default.
• W1969499569 countsByYear W19694995692023 @default.
• W1969499569 crossrefType "journal-article" @default.
• W1969499569 hasAuthorship W1969499569A5010046302 @default.
• W1969499569 hasAuthorship W1969499569A5028151790 @default.
• W1969499569 hasAuthorship W1969499569A5053945938 @default.
• W1969499569 hasAuthorship W1969499569A5056106013 @default.
• W1969499569 hasAuthorship W1969499569A5081422845 @default.
• W1969499569 hasAuthorship W1969499569A5084693085 @default.
• W1969499569 hasAuthorship W1969499569A5086086952 @default.
• W1969499569 hasBestOaLocation W19694995692 @default.
• W1969499569 hasConcept C104317684 @default.
• W1969499569 hasConcept C121608353 @default.
• W1969499569 hasConcept C126322002 @default.
• W1969499569 hasConcept C145059251 @default.
• W1969499569 hasConcept C202751555 @default.
• W1969499569 hasConcept C2779013556 @default.
• W1969499569 hasConcept C2779256057 @default.
• W1969499569 hasConcept C502942594 @default.
• W1969499569 hasConcept C526805850 @default.
• W1969499569 hasConcept C54009773 @default.
• W1969499569 hasConcept C54355233 @default.
• W1969499569 hasConcept C55493867 @default.
• W1969499569 hasConcept C58207958 @default.
• W1969499569 hasConcept C71924100 @default.
• W1969499569 hasConcept C81885089 @default.
• W1969499569 hasConcept C86803240 @default.
• W1969499569 hasConcept C95444343 @default.
• W1969499569 hasConceptScore W1969499569C104317684 @default.
• W1969499569 hasConceptScore W1969499569C121608353 @default.
• W1969499569 hasConceptScore W1969499569C126322002 @default.
• W1969499569 hasConceptScore W1969499569C145059251 @default.
• W1969499569 hasConceptScore W1969499569C202751555 @default.
• W1969499569 hasConceptScore W1969499569C2779013556 @default.
• W1969499569 hasConceptScore W1969499569C2779256057 @default.
• W1969499569 hasConceptScore W1969499569C502942594 @default.
• W1969499569 hasConceptScore W1969499569C526805850 @default.
• W1969499569 hasConceptScore W1969499569C54009773 @default.
• W1969499569 hasConceptScore W1969499569C54355233 @default.
• W1969499569 hasConceptScore W1969499569C55493867 @default.
• W1969499569 hasConceptScore W1969499569C58207958 @default.

• next